RCL stock indexes fell sharply on Friday, reflecting investor concerns about the company’s prospects for further growth and a continuing struggle with the drug-overdose crisis.
The Nasdaq composite index of companies listed on the Nasdaq fell 1.4%, the S&P 500 index of stocks down 1.7%, and the Dow Jones industrial average index of the stocks down 0.4%.
The RCL shares market was down nearly 5% on Friday.
The company posted a loss of $5.1 billion in the year to the end of March, with a net loss of nearly $3.5 billion, according to data compiled by Bloomberg.RCL stock is up by more than 20% this year, according the Nascom report, which is the most for any stock in the company since the start of the crisis.
Investors are betting on a recovery in sales, profit margins and earnings, but some have said they may be nervous about the drug company’s future growth prospects.
Rcl shares have been trading down since the end (of March) of last year, with investors wary of drug-related sales.
The drug company, based in St. Louis, Missouri, said in December that it would cut more than a quarter of its workforce as a result of the drug crisis.RCl said it would spend more than $100 million on hiring and support staff to help customers and the community.
RCL has also announced plans to hire more than 100 new employees over the next two years.